|1.||Wei, Duo: 9 articles (04/2006 - 05/2003)|
|2.||Kipling, David: 6 articles (01/2013 - 11/2005)|
|3.||Davis, Terence: 6 articles (01/2013 - 11/2005)|
|4.||Marber, Michael S: 5 articles (06/2010 - 08/2003)|
|5.||Kim, Jae-Ryong: 5 articles (01/2009 - 01/2003)|
|6.||Lee, Kyung Hee: 5 articles (01/2009 - 01/2003)|
|7.||Chen, Xu-lin: 5 articles (04/2006 - 04/2004)|
|8.||Ben, Dao-feng: 5 articles (04/2006 - 04/2004)|
|9.||Xia, Zhao-fan: 5 articles (04/2006 - 04/2004)|
|10.||Kumphune, Sarawut: 4 articles (01/2015 - 05/2008)|
01/01/2015 - "Microglial interleukin-1β over-expression in Vc was induced by trapezius muscle inflammation, which was significantly suppressed by SB203580 administration. "
10/01/2009 - "P38MAPK regulates the inflammation and apoptosis in the SN of the mouse model of subacute PD, and SB203580 may provide some neuroprotective effect."
05/01/2009 - "We used the p38MAPK inhibitor SB203580 and a whole human genome microarray in an in vitro inflammation model to identify genes regulated by this pathway in human chondrocytes. "
12/01/2007 - "Furthermore, the p38 inhibitor SB203580 attenuated toxin A-induced inflammation in vivo in the mouse ileum, evidenced by a significant decrease in neutrophil infiltration, villous destruction, and mucosal congestion. "
03/01/2006 - "Treatment of proliferating cells with the p38 specific inhibitor SB203580 inhibited the inflammation induced activation of p38 and the synthesis of SIP24. "
04/16/2010 - "p38 inhibitor (SB203580) blocked hypoxia-induced Bcl-2 expression, whereas PKC, ERK1/2 and PI3K inhibitors did not. "
04/01/2008 - "Furthermore, hypoxia inducible factor-1alpha (HIF-1alpha) was detected in vivo after LPS administration but its expression was not affected by SB203580. "
04/01/2001 - "Administration of SB 203580 (1-10 microM) before and during the preconditioning protocol, had no effect on cell morphology and viability after 2 h hypoxia, compared to untreated preconditioned cardiomyocytes. "
07/01/2007 - "In addition, the in vitro treatment of cardiac myocytes with SB203580 also abolished the upregulation of cPLA2 and the disturbance of phospholipid homeostasis elicited by hypoxia and burn serum challenge. "
02/01/2007 - "In the same experiment, the effect of SB203580 on cPLA2 expression in rat myocardial cells was determined after hypoxia and burn serum treatment in vitro. "
09/01/2009 - "Treatment with SB203580 significantly attenuated burn-induced intestinal permeability (212 microg/mL versus 81 microg/mL, P<0.05), and decreased expression of intestinal MLCK resulting in decreased phosphorylation of MLC. "
02/01/2007 - "Wistar rats were randomized into normal group (n = 8), burn(n =40) , burn and SB203580(n = 16), burn and isotonic saline( n = 16) groups, with 8 rats at each time-points. "
12/01/2005 - "The specific inhibitor of p38MAPK (SB203580 in 10 mg/kg) was given to the rats in the burn with SB203580 group at 15 minutes and 12 hours after burn. "
08/01/2008 - "Low level of p-Akt induced by burn serum increased after treatment of SB203580 (P < 0.01), which inhibited the release of CK induced by burn serum. "
05/01/2001 - "percent burn(-1)), and 4) burn rats given injury and fluid resuscitation plus SB203580. "
09/01/2011 - "Hepatocytes necrosis, recruitment and proliferation of leucocytes in liver and spleen were found to be inhibited by administration of SB203580. "
06/01/2005 - "These results suggest that treatment with SB-203580 during reperfusion aggravates myocyte necrosis but concomitant blockade of contractile force unmasks cardioprotective effects of SB-203580."
04/01/2000 - "SB203580 also blocked monocyte necrosis and IL-1beta release caused by toxin A but not by other toxins. "
02/01/2006 - "Treatment with P188 inhibited p38 activation; however, direct inhibition of p38 by SB203580, which selectively inhibits the activity of the p38 MAPK, provided only partial inhibition of apoptosis and had no effect on necrosis. "
04/01/2002 - "CD3/CD28 double stimulated caudal lymph node cells of SB 203580 treated mice showed decreased interferon gamma production but increased tumour necrosis factor alpha production. "
05/01/2013 - "(1) 27 Balb/c mice were divided randomly into three groups: DSS-induced colitis group, normal control group and SB203580 treatment group. "
09/01/2005 - "Furthermore, SB203580 prevented BFT-induced colitis in the mouse ileum, as evidenced by significant decreases in villous destruction, neutrophil infiltration, and mucosal congestion. "
10/01/2004 - "The goal of this study was to evaluate the effects of the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 on inflammatory responses using the DSS-induced experimental colitis model in mice reflecting human IBD. "
08/01/2006 - "We sought to evaluate the expression and activity of p38 and JNK MAPK in IBD and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis; and the effects of a p38 inhibitor, SB203580, in TNBS colitis. "
04/01/2002 - "In this paper we describe the effects of a specific p38 MAPK inhibitor, SB 203580, in trinitrobenzene sulphonic acid (TNBS) induced colitis in mice. "
|1.||p38 Mitogen-Activated Protein Kinases
|2.||Protein Kinases (Protein Kinase)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||salicylhydroxamic acid (SHAM)
|8.||Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
|10.||Messenger RNA (mRNA)